Development Of A Simple Chemical Test For Detecting DNA-interacting Compounds For Medical And
Funder
National Health and Medical Research Council
Funding Amount
$315,450.00
Summary
The project exploits a simple chemical reaction to detect and measure the interaction of compounds with DNA. The test will be useful in the early screening of drug candidates for genotoxicity, identifying new anticancer drugs and also find application in the environmental, cosmetic and food industries. Work will focus on establishing peak conditions for the test, determining the scope of application, testing a panel of control compounds and performing a blind study to provide proof of concept.
Spectrometer Module For Surface Enhanced Raman Scattering Spectroscopy In Glucose Analysis
Funder
National Health and Medical Research Council
Funding Amount
$385,151.00
Summary
Scientists have developed a number of incredibly powerful and sophisticated techniques to identify chemicals and measure their concentrations in the laboratory. However, it remains a major challenge to perform these measurements under everyday circumstances. For example, surface-enhanced Raman scattering (SERS) has gained widespread recognition as a technique for trace chemical detection, but it remains confined to a small number of specialist laboratories. For this reason, Dr Paul Stoddart at S ....Scientists have developed a number of incredibly powerful and sophisticated techniques to identify chemicals and measure their concentrations in the laboratory. However, it remains a major challenge to perform these measurements under everyday circumstances. For example, surface-enhanced Raman scattering (SERS) has gained widespread recognition as a technique for trace chemical detection, but it remains confined to a small number of specialist laboratories. For this reason, Dr Paul Stoddart at Swinburne University of Technology recognised a need for more practical SERS probes for field applications. His team has now developed a proprietary SERS probe, based on an optical fibre that is little thicker than a hair. These optical fibres can form the core element of field-portable SERS spectrometers. This work has recently been boosted by the discovery in the United States that SERS can be used to monitor glucose in blood. The development of a continuous glucose monitor has long been a holy grail of sensor research, because of the millions of diabetes sufferers who regularly perform the painful finger prick test. For SERS to provide a practical solution to glucose monitoring, it is recognised that SERS optical fibres are needed for minimally invasive probes. With support from Biopharmica and the Diabetes Australia Research Trust, Dr Stoddart's team has now demonstrated that sensitive SERS probes can be produced in large quantities. The next objective is to develop a prototype low-cost SERS spectrometer for use as part of a continuous glucose monitoring system. This will require the development of a laser source and spectroscopic system that can interface to the SERS probes. It is proposed to use an Australian designed and manufactured laser system based on a low-power narrow-linewidth laser diode. The project plans to bring together Swinburne University, OptoTech and Grey Innovation in order to develop a commercially scaleable and robust device.Read moreRead less
We will conduct a clinical trial of the effectiveness of a continuous auditory display of an anesthetized patient's respiratory status. Expired carbon dioxide monitoring has helped reduce respiratory incidents since its widespread introduction in the late 1980s, but a continuous auditory display of respiratory status may reduce incidents further. We will conduct a clinical trial with 10 anaesthetists of continuous auditory respiratory monitoring. Successful outcome may lead to commercial uptake.
Development Of A Prototype Production System For Optical Fibre Diagnostic Probes
Funder
National Health and Medical Research Council
Funding Amount
$191,598.00
Summary
Advances in nanotechnology have led to new techniques for the precise fabrication of nanometre scale structures. A recent breakthrough by the applicants now allows high-quality nanostructures to be stamped onto the tip of low-cost optical fibre probes. When coated with silver, these sensitive probes can be used for continuous monitoring of blood glucose in diabetics and in critical care situations. This project aims to develop a prototype manufacturing system for optical fibre glucose probes.
Development And Evaluation Of A New Cochlear Implant Sound Processing Strategy Utilising A Spike-based Temporal Auditory
Funder
National Health and Medical Research Council
Funding Amount
$98,000.00
Summary
This project aims to improve cochlear implant users’ perception of speech, particularly in noisy environments, by developing a new sound processing strategy that is based on the human physiological response to sound. To date, cochlear implant sound processing strategies have been designed using simple engineering principles. Our new strategy simulates the behaviour of the cochlea and the auditory nerve to give a stimulation sequence closer to normal hearing. This project will demonstrate the fea ....This project aims to improve cochlear implant users’ perception of speech, particularly in noisy environments, by developing a new sound processing strategy that is based on the human physiological response to sound. To date, cochlear implant sound processing strategies have been designed using simple engineering principles. Our new strategy simulates the behaviour of the cochlea and the auditory nerve to give a stimulation sequence closer to normal hearing. This project will demonstrate the feasibility of this approach and show the level of benefit that is provided over existing cochlear implant processing strategies. This project aims to implement the STAR strategy and evaluate its effectiveness for cochlear implant users in comparison to existing commercially available strategiesRead moreRead less
Phase 1 Clinical Trial Of Autologous Dendritic Cells To Induce Antigen-specific Tolerance
Funder
National Health and Medical Research Council
Funding Amount
$165,125.00
Summary
We have previously generated modified dendritic cells in mice with the ability to suppress immune responses once they have started. This project will develop the dendritic cell vaccine as a platform technology for human clinical use. We aim to demonstrate, in a phase I clinical trial, the capacity of modified human autologous dendritic cells to suppress the immune response to a model antigen in a group of healthy volunteers and a group of patients with rheumatoid arthritis taking drugs for their ....We have previously generated modified dendritic cells in mice with the ability to suppress immune responses once they have started. This project will develop the dendritic cell vaccine as a platform technology for human clinical use. We aim to demonstrate, in a phase I clinical trial, the capacity of modified human autologous dendritic cells to suppress the immune response to a model antigen in a group of healthy volunteers and a group of patients with rheumatoid arthritis taking drugs for their diseaseRead moreRead less
Biological, Functional And Radiographic Evaluation Of Autologous Chondrocyte Implantation
Funder
National Health and Medical Research Council
Funding Amount
$307,400.00
Summary
We will test the hypothesis that autologous chondrocyte implantation (ACI) and extensor realignment produces superior clinical, biological and radiographic results when compared with conventional treatment of realignment and debridement. We will specifically address the following aims: 1. Quantify the clinical outcome of ACI compared to the traditionally used treatment of debridement through the use of functional evaluation in a blinded randomised controlled clinical trial; 2. Evaluate the radio ....We will test the hypothesis that autologous chondrocyte implantation (ACI) and extensor realignment produces superior clinical, biological and radiographic results when compared with conventional treatment of realignment and debridement. We will specifically address the following aims: 1. Quantify the clinical outcome of ACI compared to the traditionally used treatment of debridement through the use of functional evaluation in a blinded randomised controlled clinical trial; 2. Evaluate the radiographic changes in the patellofemoral joint that occur as a result of ACI, using high resolution magnetic resonance imaging (MRI) to quantify the regeneration of hyaline articular cartilage; 3. Using the new technique of confocal arthroscopy, we will compare the histologic appearances of the ACI graft and its interface with adjacent articular cartilage; 4. Evaluate patient, surgical and explant chondrocyte characteristics in relation to functional, radiographic and biological outcomes. With respect to the matrix-induced autologous chondrocyte implantation (MACI) technique, we wish to clarify the clinical practice as a definitive treatment for articular cartilage defects. This will be the first randomised, controlled clinical trial of the MACI technique compared to that used by other groups. A positive clinical outcome from this trial will help promote the three cornerstones of this procedure – successful cell culture, efficient surgical procedures, and complimentary postoperative rehabilitation. Furthermore, this research will: a) Enhance the expansion of the MACI technique; b) Encourage development of endoscopic techniques of implantation using a combination of – • Preoperative defect registration with MRI • pre-cut custom patches, implanted with • Computer-assisted navigation techniques: c) Increase the potential to cater for a larger number of patients requiring articular cartilage repair; d) Confirm the long-term durability of regenerated cartilage in the 4th year and beyond; e) Add further commercial value by demonstrating MACI may prevent the onset of osteoarthritis.Read moreRead less
Development Of An Anti-GM-CSF Antibody For Treatment Of Rheumatoid Arthritis
Funder
National Health and Medical Research Council
Funding Amount
$283,000.00
Summary
The aim of this project is to develop assays for the evaluation of the efficacy and safety of an anti-GMCSF neutralizing antibody in a Australian first-in-man clinical trial in patients with severe rheumatoid arthritis (RA). This chimeric antibody has been developed by the Ludwig Institute for Cancer Research, Melbourne Branch, in conjunction with KaloBios Pharmaceuticals, Inc., USA. It is intended to use the assays developed in this project to facilitate commercial development of this antibody, ....The aim of this project is to develop assays for the evaluation of the efficacy and safety of an anti-GMCSF neutralizing antibody in a Australian first-in-man clinical trial in patients with severe rheumatoid arthritis (RA). This chimeric antibody has been developed by the Ludwig Institute for Cancer Research, Melbourne Branch, in conjunction with KaloBios Pharmaceuticals, Inc., USA. It is intended to use the assays developed in this project to facilitate commercial development of this antibody, and result in the development of an improved treatment for this devastating disease.Read moreRead less